Literature DB >> 2283524

Diurnal differences in response to oral levodopa.

J P Frankel1, Z Pirtosek, P A Kempster, M Bovingdon, R Webster, A J Lees, G M Stern.   

Abstract

Diurnal differences in duration and quality of motor response to levodopa are frequently described by patients. The quality and duration of motor responses were objectively assessed to morning and afternoon oral levodopa doses in five patients with Parkinsonian motor fluctuations who complained of diurnal variation in response to their normal levodopa medication. Results suggest that under controlled conditions which eliminated the effects of diet and overlapping levodopa effects the response to levodopa remained unchanged throughout the day, and that the duration of response could be predicted by plasma levodopa levels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2283524      PMCID: PMC488274          DOI: 10.1136/jnnp.53.11.948

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  12 in total

1.  3-O-methyldopa uptake and inhibition of L-dopa at the blood-brain barrier.

Authors:  L A Wade; R Katzman
Journal:  Life Sci       Date:  1975-07-01       Impact factor: 5.037

2.  Does an inhibitory action of levodopa contribute to motor fluctuations?

Authors:  J G Nutt; S T Gancher; W R Woodward
Journal:  Neurology       Date:  1988-10       Impact factor: 9.910

3.  Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.

Authors:  M M Mouradian; J L Juncos; G Fabbrini; T N Chase
Journal:  Ann Neurol       Date:  1987-10       Impact factor: 10.422

4.  Dietary therapy for motor fluctuations in Parkinson's disease.

Authors:  R Kurlan
Journal:  Arch Neurol       Date:  1987-11

5.  Subcutaneous apomorphine in parkinsonian on-off oscillations.

Authors:  C M Stibe; A J Lees; P A Kempster; G M Stern
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

6.  The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.

Authors:  J G Nutt; W R Woodward; J P Hammerstad; J H Carter; J L Anderson
Journal:  N Engl J Med       Date:  1984-02-23       Impact factor: 91.245

7.  Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.

Authors:  P A Kempster; J P Frankel; M Bovingdon; R Webster; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

8.  Diurnal rhythm in the central dopamine turnover in the rat.

Authors:  B Lemmer; T Berger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-07       Impact factor: 3.000

9.  Ontogeny of diurnal rhythms of central dopamine, serotonin and spirodecanone binding sites and of motor activity in the rat.

Authors:  A Bruinink; W Lichtensteiger; M Schlumpf
Journal:  Life Sci       Date:  1983-07-04       Impact factor: 5.037

10.  Behavioral and neurochemical effects of apomorphine in the cat.

Authors:  M E Trulson; T Crisp
Journal:  Eur J Pharmacol       Date:  1982-06-04       Impact factor: 4.432

View more
  4 in total

Review 1.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Diurnal effects of motor activity and fatigue in Parkinson's disease.

Authors:  J J van Hilten; G Hoogland; E A van der Velde; H A Middelkoop; G A Kerkhof; R A Roos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-08       Impact factor: 10.154

Review 3.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

4.  Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.

Authors:  Zhongping Mao; Ann Hsu; Suneel Gupta; Nishit B Modi
Journal:  J Clin Pharmacol       Date:  2013-02-20       Impact factor: 3.126

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.